
Novo Biosciences Seeks USD 5-10m in Series A for Regenerative Medicine Molecule MSI-1436 – CEO
Novo Biosciences is currently in a Series A round to raise USD 5-10m for MSI-1436, a molecule that has the potential to regenerate human tissue following a heart attack, said CEO Kevin Strange.